Exploiting lentiviral transduction for screening for miRNAs affecting Rituximab sensitivity.

<p><b>(a)</b> Schematic representation of the lentiviral vector carrying a cloned pri-miRNA sequence derived from the human genome. Further details are provided in the legend to <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0153069#pone.0153069.g001" target="_blank">Fig 1</a>. A panel of eight genomic sequences containing the miRNA sequence was inserted into vector, resulting in a set of eight lentiviral vectors. <b>(b)</b> and <b>(c)</b> Relative numbers of OCI-Ly-7 and SU-DHL-5 cells lentivirally transduced with vectors encoding eight different miRNAs. Cells were either grown in medium with Rituximab (+ RTX) or in medium without the drug and containing sodium chloride buffer as a control (–RTX). Cell numbers were determined by counting cells after staining with trypan blue. The relative number of cells was used as a growth inhibition index showing the ratio of treated cells relative to the untreated control. Statistical significance relative to the control group (cells treated with LV/miRCS-PE) is indicated by horizontal lines. Asterisks indicate level of significance as follows: *: <i>p</i> value≤ 0.05, **: <i>p</i> value≤0.01, ***: <i>p</i> value≤0.001.